As of November 6, 2026, Atara Biotherapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 12, 2026 to June 26, 2026, naming 2 appointments. The latest filing names Kevin G. Sarney, appointed (Form 8-K, June 26, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Atara Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Atara Biotherapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-12 to 2026-06-26. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Atara Biotherapeutics, Inc. files it.
Layoffs on record: about 15 jobs, latest 2025-10-07 (layoff filings and notices).
Also on the record for Atara Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 7.6% of the class | 5%+ stakes | Source |
| July 24, 2026 | Stake report, Schedule 13D/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13D/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G, by Adage Capital Management, L.P. | 8.56% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13D/A, by Panacea Innovation Limited | 16.1% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 6.2% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 17.4% of the class | 5%+ stakes | Source |
| January 14, 2026 | Stake report, Schedule 13D/A, by Panacea Innovation Limited | 19.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13D/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 9.9% of the class | 5%+ stakes | Source |
| August 19, 2025 | Stake report, Schedule 13D/A, by Panacea Innovation Limited | 20% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Atara Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Atara Biotherapeutics, Inc. and the records around it.
Atara Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Oct 2025
- Who owns it
Companies that share a holder
- Panacea Innovation Limited also filed stake reports on 3 other companies: Connect Biopharma Holdings Limited (Apr 2026), CASI Pharmaceuticals, Inc. (Dec 2025), Adagene Inc. (Nov 2025)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
Watch Atara Biotherapeutics, Inc.
Get an email when Atara Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Atara Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Atara Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Atara Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-26 | In | 2026-06-26 | 8-K, 2026-06-26 | ||
| 2026-06-12 | In | Director | 2026-06-11 | 8-K, 2026-06-12 |
Who leads Atara Biotherapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Brian Cherry, appointed, effective 2026-06-11 (filed 2026-06-12).
New leaders reset buying decisions — get the Full Report on Atara Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Atara Biotherapeutics, Inc., with the record behind each one.
Find candidates like Director at Atara Biotherapeutics, Inc.Every change, in the filing's words
Appointed: Kevin G. Sarney, effective 2026-06-26
(c) On June 26, 2026, the Company's Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc. ("CRCFO"), as interim chief financial officer, effective as of June 26, 2026.
- (b) On June 22, 2026, Atara Biotherapeutics, Inc. (the "Company") notified Yanina Grant-Huerta, the Company's Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026.
- In connection with his appointment, Mr. Sarney will serve as the Company's principal financial officer and principal accounting officer.
- Mr. Sarney will provide interim chief financial officer services pursuant to a consulting agreement with CRCFO to which the Company is a party (the "Consulting Agreement").
- Under the Consulting Agreement, the Company will pay CRCFO an agreed upon hourly rate for Mr. Sarney's services.
- Mr. Sarney will not receive any compensation directly from the Company.
- The Consulting Agreement may be terminated by either the Company or CRCFO upon 30 days written notice.
- Mr. Sarney will enter into the Company's standard indemnification agreement for directors and executive officers.
- Mr. Sarney, age 61, has over 25 years of finance and accounting experience with life science companies.
- Since January 2021, Mr. Sarney has served as a consultant at CRCFO, a provider of strategic and operational finance and accounting services for life science companies.
- Prior to joining CRCFO, Mr. Sarney served in executive finance positions with a number of publicly traded and privately held life science companies.
Appointed: Brian Cherry, Director, effective 2026-06-11
On June 11, 2026, the Board of Directors (the " Board ") of Atara Biotherapeutics, Inc. (the " Company ") appointed Brian Cherry to serve as a member of the Board as a Class I director, effective June 11, 2026 (the " Effective Date ").
- Mr. Cherry was also appointed to the Audit Committee of the Board.
- The Board has determined that Mr. Cherry is independent under the Company's Corporate Governance Guidelines, applicable U.S. Securities Exchange Commission ("SEC") requirements and Nasdaq listing standards.
- Mr. Cherry will otherwise participate in the Company's non-employee director compensation arrangements, which are generally described under the heading "2025 Non-Employee Director Compensation" in the Company's Proxy Statement for its 2026 Annual Meeting of Stockholders as filed with the SEC on April 24, 2026 (the "Proxy Statement"), including an annual cash retainer of $55,000 starting on the Effective Date, with payment pro-rated for any partial period of service.
- The Company also entered into its standard form of indemnification agreement with Mr. Cherry.
Tools for this story
Each opens in a new tab, filled in for Atara Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.